The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
MHRA approves adrenaline nasal spray - the first needle-free emergency treatment for anaphylaxis in the UK
|MHRA